Express News | Sanofi invested 0.6 billion euros (equivalent to 0.595 billion US dollars) to establish the Modulus vaccine facility in Singapore. This will create approximately 200 job opportunities locally, and it is expected to be fully operational by mid-2026.
Sanofi Opens New $600 Million Vaccines Facility in Singapore
Pharmaceutical giant Sanofi invests nearly 0.6 billion dollars to build a factory in Singapore to produce vaccines.
French pharmaceutical giant Sanofi announced on Wednesday that it will build a new factory in Singapore to produce vaccines and other pharmaceuticals to strengthen preparedness for emergencies, including potential epidemics. According to a statement, this factory named Modulus is invested in the Biopolis biopharmaceutical park in Singapore with 0.8 billion Singapore dollars (nearly 0.6 billion US dollars). It can simultaneously produce up to four vaccines or biopharmaceuticals and is expected to be fully operational by mid-2026, creating 200 technical job positions in Singapore. The company stated that Modulus can also be reconfigured within a few days to allow for transfers between technology platforms.
Sanofi (SNY.US) / Regeneron (REGN.US) Dupilumab injection approved for clinical treatment of pure lichen in China.
The dupilumab injection submitted by Sanofi (SNY.US) has been approved for a new clinical trial implicit license.
Bird Flu Found In Raw Milk Leads To Recall In California
NSC, Sanofi, and A*STAR Partner to Advance Acne Treatment Research